340B hospitals and health centers say they have a lot of questions about new requests from Express Scripts (ESI) to verify 340B drug reimbursement claims in 10 business days.
Hospital and health center covered entities report getting one or more
…
Month: April 2022
The federal government on Monday accused a Tennessee health system of unlawfully paying a Memphis-area private oncology practice for patient referrals, letting the system “recoup a staggering discount in costs” through the 340B program. The 340B health system—Methodist Le Bonheur
…
SPONSORED CONTENT
Managing a hospital, clinic or specialty pharmacy grows more challenging with each passing day. Whether you are considering opening a new pharmacy or already operate one or multiple locations, existing and emerging complexities challenge daily pharmacy operations and financials.
Research conducted by Sage Growth Partners, a strategic healthcare-based marketing and research firm, reveals that community health centers (FQHCs) and hospital pharmacy leaders worry about scarcity and quality of labor, complex third-party payor contracting, and evolving compliance guidelines. Their concerns are rooted in the impact these issues have on patient access and outcomes, as well as profitability.
These concerns go above and beyond core pharmacy operations. Pharmacists and their staff face the unrealistic expectation to be highly knowledgeable about best practices for hiring and retaining employees, having the financial and contractual prowess to optimize drug purchasing and payor contracting, and even how to license and maintain accreditation in the complex regulatory world. However,
…
The federal government, as expected, is challenging a federal district judge’s February opinion and March final orders in drug manufacturer AstraZeneca’s 340B contract pharmacy lawsuit.
The U.S. Justice Department (DOJ) announced the appeal in a one-sentence court filing on April
…
Today is the last day for hospitals that have lost their 340B eligibility due to the COVID-19 public health emergency to file paperwork to be reinstated to the drug discount program.
A federal spending bill signed on March 15 included
U.S. Health and Human Services Secretary Xavier Becerra has extended the COVID-19 public health emergency for another 90 days, through July 15. It was due to end on Saturday, April 16.
Major hospital groups and group purchasing organizations asked Becerra
…
Astellas Pharma is issuing 340B covered entities refunds for overcharges on three NDCs for its prostate cancer treatment Xtandi and on four NDCs for its overactive bladder medication Myrbetriq for the period from Q3 2020 through Q2 2021.
Astellas posted
SPONSORED CONTENT
Numerous studies have demonstrated how patient medication adherence impacts long-term outcomes and healthcare costs.
Drug manufacturers consistently work to refine their current products, and to create new ones, in order to increase patient adherence. Medications that once needed to be administered multiple times per day, now come in extended-release versions that require only one daily dose. Manufacturers have succeeded in combining multiple drugs into single tablet regimens. This trend is evident in the evolution of HIV regimens over time. One of the first combinations of anti-retroviral therapy used to treat HIV patients required patients to take almost 20 pills per day. Now, many of the most widely used medications for managing HIV consist of only one pill, once per day.
The Next Generation
Recently, manufacturers have taken it a step further–introducing long-lasting injectable medications. Examples include Cabotegravir/rilpivirine (CABENUVA), a monthly injection to manage HIV, and long-acting buprenorphine (SUBLOCADE®), a once-a-month injection, used to help manage opioid addiction.
…
A federal appeals court in Chicago has told a lower court in Indianapolis to issue a final judgement in drug manufacturer Lilly’s 340B contract pharmacy lawsuit to clear the way for the case’s next phase.
An appeals court in Philadelphia
…
Drug manufacturer Lilly is giving 340B covered entities refunds for overcharges on 14 NDCs during Q3 2019 after restating Medicaid average manufacturer prices and best prices “to account for lagged transactional data,” the company says on a notice on the
…